Abstracts tagged "MSCs and ev"

Abstract Number: 1986 • 2019 ACR/ARP Annual Meeting
Insights into Osteoarthritis Progression by Gene Expression and miRNA Profiling of Mesenchymal Stromal Cells from Medial and Lateral Femoral Condyles
Clara Sanjurjo-Rodríguez ¹, Rachel Crossland ², Thomas Baboolal ³, Monica Reis ⁴, Agata Burska ⁵, Frederique Ponchel ⁵, Jehan El-Jawhari ⁵, Dennis McGonagle⁶, Hemant Pandit ⁷, Xiao-nong Wang ⁸ and Elena Jones ⁹, ¹Grupo de investigación en Terapia Celular y Medicina Regenerativa. Departamento de Fisioterapia, Medicina y Ciencias Biomédicas. Universidade da Coruña. Agrupación estratégica CICA-INIBIC. A Coruña, España; University of Leeds; Newcastle University, A Coruña, Spain, ²2Institute of Cellular Medicine, Newcastle University, Newcastle, United Kingdom, ³Leeds Institute of Rheumatic and Musculoskeletal Medicine (LIRMM)University of Leeds, Leeds, United Kingdom, ⁴Department of Pediatrics, Harvard Medical School, Boston, MA, USA, Boston, ⁵Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom, ⁶University of Leeds, Leeds, United Kingdom, ⁷Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds. NIHR Leeds Musculoskeletal Biomedical Research Unit, Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom, ⁸Institute of Cellular Medicine, Newcastle University, UK, Newcastle, United Kingdom, ⁹University of Leeds, Leeds, England, United Kingdom
Background/Purpose: Bone marrow multipotential stromal cells (MSC) are widely used in clinical trials to treat bone and cartilage diseases. However, there is limited information on…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].